Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
xxb750
- Development stage
- Phase 2
- Lead developer
- Novartis
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
XXB750 is an investigational fully human monoclonal IgG1 antibody developed by Novartis for the treatment of resistant hypertension (rHTN) and heart failure with reduced ejection fraction (HFrEF). It acts as a selective agonist of natriuretic peptide receptor 1 (NPR1), mimicking the effects of atrial natriuretic peptide by increasing plasma cGMP, lowering blood pressure, and promoting diuresis. The drug is administered via subcutaneous injection. In clinical studies, XXB750 demonstrated safety and tolerability in patients with rHTN and HFrEF; however, development was discontinued after Phase II trials due to sponsor decision[1][3][6].
02
Targets
NPR1 (Natriuretic peptide receptor 1)
Beyond the preview
Go deeper on xxb750.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on xxb750.